Sanofi, Evotec team up for research on infectious diseases treatment
PARIS: Sanofi and Evotec said they had started exclusive talks over accelerating research into the treatment of infectious diseases, and added on Thursday that they would form a new open innovation platform in this area, led by Evotec.
Sanofi will license its research into infectious diseases and its early-stage development portfolio, and the French group will also transfer its research unit dealing with this area over to Evotec.
Sanofi will pay Evotec an initial one-time cash upfront payment of 60 million euros ($74.4 million) and provide further significant long-term funding to develop portfolio, the companies added.
(Reporting by Sudip Kar-Gupta; Editing by Gopakumar Warrier)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd